World Biosimilar Congress 2017

The 6th annual World Biosimilar Congress is coming to Basel 31st October – 1st November. Once again it will be covering all the key issues within biosimilar development, manufacture, market access and regulations, all in one jam packed two-day event.

Across the two days, industry and thought-leading speakers from across the globe will come together to network and discuss the key issues on biosimilar drug development and healthcare uptake. Key topics will include:

- The Global R&D and Regulatory Landscape
- Designing Biosimilar Development Programmes
- Bioanalytics for Biosimilars
- Characterisation and Comparison of Biosimilars to Originators
- Extrapolation and Interchangeability
- Pharmacovigilance in Biosimilars
- Legal Considerations for Biosimilars
- Biosimilar Uptake and Market Considerations
- Increasing Purity and yield in Biosimilar Production

Prices:
Final standard price: EUR 2340
Final academic price: EUR 1170

Speakers: Elena Wolff-Holz, Chair of the Biosimilar Medicinal Products Working Party of the CHMP (BMWP), EMA / Benedicte Lunddahl, Team Leader, Pharmacovigilance, Danish Medicines Agency / Erin Federman, Global Director, Team Lead, Immunology Biosimilars, Boehringer Ingleheim / Ingrid Schwarzenberger, Head Global Regulatory Affairs, Sandoz Biopharmaceuticals / Adam Levysohn, Sr Director Market Access Biosimilar, Biogen / Uwe Gudat, Head of Safety, Biosimilars, Merck / Margaret Dolan, Specialist Procurement Pharmacist, Procurement Team, NHS Commercial Solutions / Ber Oomen, Executive Secretary, European Specialist Nurses Organisations / Andrew J. G. Simpso, Scientific Director, Orygen Biotecnologica / Andrew Spiegel, Executive Director, Global Colon Cancer Assn. / Anjan Selz, Vice President – Head of Biosimilars EMEA, Lupin Europe Ltd / Alain Beck, Senior Director Analytical Chemistry, CIPF and Associate Editor, mAbs / Benedicte Lunddahl, Team Leader, Pharmacovigilance, Danish Medicines Agency

Category: Conferences, Science, Health and Medicine,